Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with Locally Advanced MMR-deficient Colon Cancer By Ogkologos - November 22, 2024 692 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NICHE-3 study Source RELATED ARTICLESMORE FROM AUTHOR Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less FDA Approves Acalabrutinib with Venetoclax for CLL or SLL MOST POPULAR Cancer research in 2020: A spotlight on Manchester December 27, 2020 Kinder and more effective – why childhood cancers need specific treatments September 3, 2021 How Some Brain Tumors Hijack the Mind to Grow June 21, 2023 Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 Load more HOT NEWS Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic...
